Lilly’s Jaypirca receives CHMP positive opinion for CLL in Europe

Lilly has received the CHMP of the EMA positive opinion for Jaypirca (pirtobrutinib) to treat chronic lymphocytic leukaemia (CLL) in adults. The Jaypirca application moves to the EC for a decision, expected within the next one to two months. Results from the BRUIN CLL-313 and BRUIN CLL-314 studies supported the application. Credit: Sai Thaw Kyar/Shutterstock.com. Eli Lilly and Company has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for Jaypirca (pirtobrutinib) to treat chronic lymphocytic leukaemia (CLL) in adults. This Jaypirca CHMP recommendation for CLL applies across all…

Source: Pharmaceutical Technology